SOUP

[soupoftheday]

32 Stem Cell Companies to Watch

by: Mike Havrilla February 04, 2009

| about stocks: ACTC / ASTM / ATHX / BHRT / BTIM / CBAI.OB / CCEL.OB / CUR / CYTX / ILE / KOOL / MBLTY.PK / NBS / OPXA / OSTE / PSTI / RTIX / STEM


http://seekingalpha.com/article/118356-32-stem-cell-companies-to-watch?source=yahoo

[soupoftheday]

http://www.digitalpodcast.com/podcastnews/2007/11/08/bsg-clearing-solutions-lance-devin-talks-about-mobile-payments/

[soupoftheday]

Guard Dog Approved with Largest U.S. Clearing House

[soupoftheday]

Legal Club of America - http://www.legalclub.com/identity_theft_solutions-identity_theft.asp
Service Delivery — Identity Protection Plan:
http://www.guarddogid.com/index.php/terms_and_conditions#terms14

* e. enroll customer in an ID theft legal protection plan, such as the one provided by Legal Club of America, for the duration of their enrollment in The Companys identity protection plan.

[soupoftheday]

Initial Company Information and Disclosure Statement - Guard Dog Inc. Business Disclosure Statement

[soupoftheday]

http://www.valueclickmedia.com/dm_lead_gen_registration.shtml

[soupoftheday]

http://www.cumbrowski.com/leadgen.asp#coreg

[soupoftheday]

http://exclusivepath.com/faq.php

[soupoftheday]

http://webpodge.com/2006/09/06/co-registration-why-you-might-want-to-add-this-to-your-site/

[soupoftheday]

http://www.activeprospect.com/co-registration.html

[soupoftheday]

http://www.coregistrationpath.com/

[soupoftheday]

http://www.pureads.com/about.php

[soupoftheday]

http://www.myxer.com/

[soupoftheday]

Administrative Contact:
ModernAd Media, LLC.
Nathan Schulman ([e-mail])
+1.5619615307
Fax:
2701 NW Boca Raton Blvd
111
Boca Raton, FL 33431
US

Technical Contact:
ModernAd Media, LLC.
Nathan Schulman ([e-mail])
+1.5619615307
Fax:
2701 NW Boca Raton Blvd
111
Boca Raton, FL 33431
US

[soupoftheday]

Description:
We are seeking an experienced .Net programmer to develop a variety of web-based applications. A thorough understanding of computer science principles is desired. The majority of our work is done using C#, but experience with T-SQL, Javascript, HTML, XML, and other common web technologies is required.

ModernAd Media specializes in Internet marketing and provides developers a unique opportunity to do new development using the latest technologies. This is not a maintenance position. You will be developing new systems. However, you will also be expected to familiarize yourself with the existing code and provide support for that code as needed.

Primary Contact
ModernAd Media
6420 Congress Avenue
Suite 1800
Boca Raton, FL 33487
Phone: [phone]

[soupoftheday]

https://www.pscpublicaccess.alabama.gov/pscpublicaccess/ViewFile.aspx?Id=6567e5aa-a070-413b-9018-18bbace05ac0

[soupoftheday]

http://www.optionseducation.org

[soupoftheday]

http://www.klinternational.net/

[soupoftheday]

http://www.legalclub.com/training/agent_training/agent_training_files/frame.htm

[soupoftheday]

http://www.edentify.us/press/view-article.php?feed_id=4&article_id=180

[soupoftheday]

[soupoftheday]

I am getting conflicting reports....I don't know???

[Kristallweizen]

So is today the WEHI merger day?

[soupoftheday]

Opexa Therapeutics, Inc http://www.pharmabiz.com/article/detnews.asp?articleid=45947

[soupoftheday]

http://www.stemcellthera.com/

[soupoftheday]

HealthFirst-Adult stem cell therapy
Wednesday, February 27, 2008 | 2:28 PM
Medical news from abc12.comBy Leslie LoBueUNDATED (WJRT) --

(02/26/08)-- Most of what you hear about stem cells has to do with the controversy surrounding them, but they are helping cancer patients.

A review of clinical trials involving adult stem cells during the past ten years indicates they are helping patients who have a variety of diseases and even heart trouble.
Adult stem cell therapy has become a standard of care when treating several types of cancer.

HealthFirst reporter Leslie LoBue says one patient diagnosed with multiple sclerosis says his symptoms are gone.

Barry Goudy was diagnosed with multiple sclerosis in 1995. He began to lose feeling in his left leg, and as trouble with his central nervous system progressed, he started to lose his vision.

"You sit and you cry and you wonder why you and then I went back to my neurologist and said tell me how I can fight this," he recalled.

He enrolled in a clinical trial in 2003. After five days of chemotherapy to destroy his immune cells, doctors used his own stem cells to rebuild his immune system.
"I have no symptoms of MS. I do no treatment for MS, I do no shots."

Dr. Richard Burt and his colleagues at Northwestern University Feinberg School of Medicine reviewed the outcomes of about 2,500 patients who had stem cell transplants. They found the cells appear to be putting some patients with autoimmune diseases in remission and offer some improvement in heart function to patients who have suffered heart attacks.
"It's a whole new approach to these diseases. Rather than just surgery or drugs that you can use, a cellular approach that seems in many different studies to be benefitting the patient," Burt explained.

The review appears this week in JAMA, Journal of the American Medical Association.
Unlike embryonic stem cells that result in the destruction of an embryo, adult stem cells come from your own blood or bone marrow or someone else's. The transplant appears to be safe.
" There's very low risk. Less than one percent mortality from the procedure," said Burt.

Goudy now leads an active lifestyle. He even plays with a hockey team he coaches. "I've had five years of good life. Five years. If I didn't do the transplant I would probably be in a wheelchair today."

He knows there are no guarantees how long his remission might last, but he says he's living proof stem cell transplants do work.
Stem cell clinical trials for liver disease have recently started, and trials for cerebrovascular disease and spinal cord injuries are being considered. If you would like more information about where these trials are taking place and how to get involved you can go to the government's clinical trials Web site by clicking the link in the right margin of this story.

To contact Dr. Richard Burt, call Marla Paul at Northwestern University Feinberg School of Medicine at 312-503-8928

[soupoftheday]

http://web.archive.org/web/20030204212623/www.proteex.com/management.html

[soupoftheday]

PharmaFrontiers Scientists Generate Human Insulin-Producing Islet Clusters
June 29, 2006 - Stem Cell Business News






PharmaFrontiers (The Woodlands, Texas ) announced June 26 that it will make two presentations at the International Society for Stem Cell Research (ISSCR) meeting in Toronto on June 29 based on data from its adult human stem cell regenerative medicine platform technologies.

The company, which recently changed its name to Opexa Therapeutics, has developed a monocyte-derived stem cell (MDSC) technology as a novel platform for the in vitro generation of highly specialized cells for potential application in autogenic cell therapy for patients with diseases such as diabetes mellitus and cardiovascular disease.

Autologous stem cell transfusion has been successfully used in bone marrow transplant for several years.

“We have developed a novel process in which we are able to generate pancreatic islet-like clusters that are glucose responsive and have the capacity to maintain glucose homeostasis in vitro for extended periods of time,” said Glenn Winner, Ph.D., director molecular biology at Opexa. “The ability of these pancreatic islet-like cell clusters to synthesize insulin in vitro may lead to an autologous islet cell transplantation therapy for the treatment of diabetes.”

Recently the company submitted U.S. patent applications for a method for the isolation and generation of monocyte-derived stem cells from human peripheral blood and for the differentiation of MDSCs into insulin-producing islet-like clusters.

The significant advantage of this technology is that it now allows the company to produce a large number of adult stem cells from a patient’s blood in a relatively short period of time.

“Our research on adult human MDSCs differentiation to islet cell clusters in the laboratory is an innovation that may lead to an autologous islet cell cluster transplantation strategy into patients with Type 1 diabetes,” said CEO David McWilliams. “The Opexa autologous therapeutic approach using MDSCs or differentiation of MDSCs should be safer and more economical than other approaches.”

According to the company, over the past year its scientists have developed a process that uses a specific set of conditions in which MDSCs are able to differentiate into insulin-producing islet-like clusters.

This process offers several distinct advantages over present adult stem cells technologies for diabetes.

One advantage of this technology is the ability to easily isolate stem cells from an individual’s circulating monocytes, expand and differentiate them into insulin-producing islet-like cluster and administer them back into the same patient.

This autologous approach avoids the problem of transplant rejection and the need for immunosuppressant drugs which are often associated with current transplantation.

The generation of insulin-producing cells from embryonic stem cells (ESCs) or other adult tissue specific stem cells requires long culture times to produce cells that typically produce relatively low levels of insulin.

Opexa’s technology allows the quick generation of insulin-producing cells in culture that function in a glucose responsive manner and express the expected pancreatic specific gene profiles that are normally observed by human pancreatic islets.

The company said current biochemical studies demonstrate that the technology is able to produce islet-like clusters that are able to synthesize and secrete insulin at physiological relevant levels.

“This is a major breakthrough and key cellular resource for the development of stem cell based therapy for the treatment of diabetes,” the company said.



PharmaFrontiers Changes Name



PharmaFrontiers on June 19 said that it changed its name to Opexa Therapeutics, Inc. and put in place a 1-for-10 (1:10) reverse split of its common stock.

The new ticker symbol, OTCBB: OPXA, went into effect the same day.

The company also announced the retirement of C. William Rouse as chief financial officer.

Lynne Hohlfeld, vice president of finance, will become chief financial officer on June 30.

Opexa’s strategy is to develop and commercialize cell therapies to treat several major disease areas such as multiple sclerosis, rheumatoid arthritis, diabetes and cardiac conditions.

The company has an exclusive license from Baylor College of Medicine for individualized cell therapies and has initiated an FDA Phase IIb clinical trial to evaluate their effectiveness in treating MS.

Contact: Lynne Hohlfeld, 281-719-3421, [e-mail], http://www.opexatherapeutics.com.

[soupoftheday]

Analytical Biotechnology Services
http://www.advancedbiochem.com/" target="_blank">http://web.archive.org/web/20001206210500/http://www.advancedbiochem.com/


Cutting edge protein assays.

Custom services for pharmaceutical and diagnostic development.

GLP/GMP to meet regulatory needs.

Analytical testing, validation, development and quality control.

From early stage through pre-clinical and clinical trials.






An Affiliate Company of The Houston
Advanced Research Center (HARC)

A Joint Venture of Bronco Technology, Inc.
and Forefront Investments

Member, Service Provider Network of the Houston Technology Center

Member, South Montgomery County
Woodlands Chamber of Commerce and





Ira L. Goldknopf, Ph.D., President [e-mail]
Helen R. Park, MS, CEO [e-mail]
Dean Morton, Director, [e-mail]
Sales and Marketing






Advanced Bio/Chem, Inc.



4800 Research Forest Drive



The Woodlands, TX 77381



Phone: [phone]



Fax: [phone]

[soupoftheday]

Helen R. Park- Patents and some of her Research Papers

1. http://www.power3medical.com/research/publications/MERGIN%20DIAGNOSTICS%20WITH%20THERAPEUTICS%20THROUGH%20PROTEOMICS.pdf

2. http://www.google.com/patents?hl=en&lr=&vid=USPATAPP11172219&id=1IygAAAAEBAJ&oi=fnd&dq=%22Helen+R.+Park%22+research+publications

3. http://www.google.com/patents?hl=en&lr=&vid=USPATAPP10301512&id=eP-IAAAAEBAJ&oi=fnd&dq=%22Helen+R.+Park%22+research+publications

4. http://www.jcb.org/cgi/content/abstract/109/3/1289

[soupoftheday]

Catherine A. Phillips "stem cell" http://search.yahoo.com/search;_ylt=A0oGkm3187dIlp8A8zBXNyoA?p=Catherine+A.+Phillips+%22stem+cell%22&fr=yfp-t-501&ei=UTF-8

[Kristallweizen]

Stem Cell Therapy links, can you imagine the huge market?

Treat Heart Disease With Your
Own Stem Cells Today!

www.vescell.com

Be 20 yrs younger & more healthy
with natural Swiss Cell Therapy.

www.YoungerYounger.com

Restore muscle strength
Sphincter control, Sexual function

www.marioizurieta.com


Scientists for Labour
http://easyweb.easynet.co.uk/~sfl/rlb_stem.htm


http://pimm.wordpress.com/2007/02/13/stem-cell-therapy-market-us-2005-2016-do-you-believe-this/





City of Cologne Germany

[soupoftheday]

http://www.regenecell.com/index.htm

[soupoftheday]

Real-World Successes of Adult Stem Cell Treatment
http://www.cogforlife.org/adultStemCellSuccess.htm

[soupoftheday]

Russian clinic:
http://translate.google.com/translate?u=http%3A%2F%2Fwww.neurovita.ru%2F&hl=en&ie=UTF-8&sl=ru&tl=en

[soupoftheday]

VesCell for Heart Disease – Treating Physicians
http://www.vescell.com/stem-cells-treating-physicians.php

[soupoftheday]

Our therapies give patients with no other options a second chance. By using the patient’s own stem cellsto heal him, our treatments can reverse the effects of debilitating degenerative diseases.

WATCH VIDEO >>> http://www.theravitae.com/index.php

[soupoftheday]

Authority on Adult Stem Cell Therapy Astounds Over 200 Physicians at Anti-Aging Conference in Nation's Capital

Last update: 12:07 p.m. EDT July 19, 2008
WASHINGTON, DC, Jul 19, 2008 (MARKET WIRE via COMTEX) -- Speaking at the 16th Annual World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies at the Gaylord National Resort in Washington, DC, on Friday, July 18, Florida-based cardiologist Dr. Zannos Grekos astounded over 200 physicians with a presentation on the impressive regenerative behavior of pre-engineered adult stem cells injected into patients with cardiomyopathy. The presentation by the lead cardiologist of Regenocyte(TM) Therapeutic ( http://www.regenocyte.com ) included a report on the company's post-stem cell treatment results citing an average increase of 21 percent in cardiac ejection rates as well as measurable improvements in a patient's congestive heart failure class status.

"We're able to bring a patient from a Class IV status to a Class II status in less than 180 days," said Grekos commenting on the success rate of Regenocyte patients receiving adult stem cell therapy to repair damage to heart muscle and arteries caused by atherosclerosis, a disease that causes heart muscle disorders and infarction due to plaque formation in the cardiac arteries in over 500,000 Americans.
According to the Congestive Heart Failure (CHF) Classification System by the New York Heart Association, patients suffering from CHF are categorized into four classes based on the disease's degree of severity. Patients in the lowest classification, Class IV, experience increased pulmonary edema, severe shortness of breath, and can be dependent on an implanted defibrillator and/or continuous infusion of Milrinone, a cardiac drug that improves blood flow by chemically increasing a patient's ejection fraction or ventricular blood pumping rate.

"I've seen patients go from an ejection fraction of 28 percent to 49 percent in six months with the stem cell therapy," he told the captive audience. (An ejection fraction of 50 is normal.) "Injecting a patient's own stem cells into damaged tissue is replacing damaged cells with normal functioning cells. At this point, the patient can discontinue Milrinone infusions and potentially the need of an implanted defibrillator."

Immediately following the presentation, over two-dozen physicians insisting on discovering more about his work approached Grekos in the hallway outside the auditorium. The group was particularly fascinated with the center's research proving that adult stem cells have the ability to engraft themselves into areas damaged by myocardial infarction (heart attacks) and turn into new heart cells and new blood vessels.
Dr. Grekos responded to the forum by stating, "Three months after treatment, cardiac nuclear scans of the areas treated reveal reversal of damage. In some cases, it's virtually impossible to identify the problems that existed before therapy. We have shown such improvement in some patients that they were taken off the heart transplant list."

In adult stem cell therapy, a patient's stem cells are extracted through a simple blood draw at the Regenocyte Clinical Center in Florida. The sample is sent to a biotechnology laboratory in Israel where the cells are cultivated and pre-engineered into millions of cardiac regenocytes (living heart repair cells). The patient receives injections of the new cells one week later at one of the clinic's internationally licensed treatment centers. Over the next few months, the cells stimulate tissue re-growth and create greater blood flow to the affected areas. Unlike surgically implanted devices, medications, or organ replacement surgery, using a patient's own stem cells to rebuild damaged heart muscles means there is no possibility of rejection or tumorgenicity (cancer causing).

Dr. Grekos and his colleagues in the world medical field are currently employing adult stem cell therapy and coordinating its application for thousands of American patients who have exhausted all other traditional therapy options. His presentation at the 16th Annual World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies conference supports efforts by a global community of doctors that are striving to incorporate adult stem cell therapy into mainstream medicine.

Dr. Zannos Grekos will be hosting several public seminars in Naples, Florida and Hilton Head, South Carolina in August 2008. He will also be a featured lecturer at another World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies conference in Las Vegas on December 11-14, 2008.
Regenocyte(TM) Therapeutic is an international corporation located in Bonita Springs, Florida. Dedicated to leading the world in providing Adult Stem Cell therapies, Regenocyte(TM) Therapeutic utilizes the most effective and safest technologies and medical procedures in order to prolong and improve the lives of its patients. A video of Dr. Grekos' presentation at the 16th Annual World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies will be available for viewing on the company's website by August 1st. Additional information on adult stem cell therapy as well as patient video testimonials, and seminar reservation requests can be found at http://www.regenocyte.com.
SOURCE: Regenocyte(TM) Therapeutic
http://www.marketwatch.com/news/story/authority-adult-stem-cell-therapy/story.aspx?guid={FF0E5398-D98E-4FF3-A388-E09C40FB8FB1}&dist=hppr

[soupoftheday]

http://www.regenocyte.com/
Welcome to Regenocyte™ Adult Stem Cell Therapy

[soupoftheday]

http://en.wikipedia.org/wiki/Stem_cell_therapy

[soupoftheday]

http://www.neostem.com/

[soupoftheday]

http://www.nyp.org/news/hospital/201.html

[soupoftheday]

http://www.cancercenter.com/stem-cell/stem-cell-unit.cfm

[soupoftheday]

http://www.thompsoncancer.com/stemcell/tcsc-stemcell-team.cfm

[soupoftheday]

http://www.xcell-center.com/

[soupoftheday]

New $225M VC Fund Aims For Dozen Stem Cell Firms; Proteus Venture Partners Plans to Invest In 10 to 15 Companies at $10-$20M Per Investment
7/28/2008

San Francisco Business Times -- A $225 million venture fund -- the first exclusively aimed at emerging stem cell companies -- looks to line up its lead investors by the end of the year, possibly by the end of September.

Proteus Venture Partners plans to invest in 10 to 15 so-called regenerative medicine companies at $10 million to $20 million per investment, said Jeffrey Karan, senior partner with the Palo Alto firm.

Its investments could range from early-stage research straight out of academia to public companies with clinical trials, from Bay Area startups to international companies, and from embryonic stem cell innovations to cord blood technology, Karan said.

"It depends on the science and the developmental stage of the science," Karan said.

Proteus, led by Anthem Venture Partners founder Greg Bonfiglio, has focused on getting its lead investors since last summer, Karan said.

It's the second such venture for Bonfiglio, whose Anthem plowed $1 million to $5 million each into 20 companies, including Advanced Cell Technology and Corus Pharma, which was acquired by Gilead Sciences. Anthem investors included some from Saudi Arabia.

The fund-raising effort for Proteus comes against the backdrop of a dour market. Venture capital in Bay Area companies totaled $2.17 billion in the second quarter, down more than 9 percent from the year before, according to Dow Jones VentureSource.

There also remain questions whether stem cell therapies can work and can make it to market in the short window typically given by venture investors.

Advanced Cell Technology Inc. -- one of the better known embryonic stem cell companies, with facilities in Alameda and Worcester, Mass. -- said July 15 that its losses from operations, negative cash flows, stockholders' deficit and liabilities are such a burden that its current cash wouldn't last beyond July 31.

Other stem cell companies also have said that they are struggling to keep enough cash on hand to make it from the lab to the bedside, the so-called "valley of death."

But Karan said stem cell company costs rise modestly as products move beyond the preclinical stage and into later-stage trials. Typical biotech company costs, on the other hand, start low and escalate significantly as trials enter their latter stages.

What's more, Proteus looks to spread its fund's cash around, not just focus on embryonic stem cells.

Stem cell investing got new attention last month when Kleiner Perkins Caufield and Byers and Highland Capital backed iZumi Bio Inc. That Mountain View startup is working with the J. David Gladstone Institutes to reprogram adult stem cells -- which researchers believe will offer the same ability as embryonic stem cells to change into any sort of tissue cell -- for cardiovascular treatments.

Karan would not identify the two "highly significant" lead investors that Proteus hopes to snag in the next couple of months or how much they will put in. Proteus, he added, is in discussions with a number of institutional investors and is looking at investors globally.

"To some extent, this reflects the fund's global focus in regenerative medicine as we are seeking to invest in the best companies from around the world, not just in the U.S.," Karan said.

Proteus' venture partners include Fayad Dandashi, who established the first private cord blood bank in Saudi Arabia; Asma Ibrahim Al Asad, a co-founder of the Dubai Cord Blood & Research Centre; Susan Lim, CEO of Stem Cell Technologies in Singapore; and J. Ward Hills, CEO of a biotech consulting firm in the United Kingdom.

Bonfiglio also is a Portola Valley neighbor of Bob Klein, the chairman of the citizens oversight board of the California Institute for Regenerative Medicine. CIRM was formed out of voter approval of Prop. 71, which authorized the sale of $3 billion in state bonds to fund stem cell research.

Bonfiglio also is on the board of VistaGen Therapeutics Inc., a South San Francisco company that is developing a diagnostic screen that could help pharmaceutical companies use stem cells to determine the toxicity of a drug.

http://www.biospace.com/news_story.aspx?StoryID=104707&full=1

[soupoftheday]

Helen R. Park
CEO
Bronco Technology, Inc.
www.broncotechnology.com


Ms. Park is an Entrepreneur, businesswoman, researcher, educator, inventor, speaker and volunteer. .

She is Founder, President, and CEO of Bronco Technology Inc., a Texas Corporation in Huntsville, TX, founder and past CEO and Chairman of the Board of Advanced Bio/Chem, Inc., d.b.a. ProtēEx (now Power3 Medical) and Cofounder of FlowGenix Corporation. Ms. Park has extensive experience in biotechnology business management and consulting. While CEO of Advanced Bio/Chem, Inc .the Company made significant discoveries in Breast Cancer and Neurodegenerative Diseases, raised over $2 Million dollars, was the 17th largest biotechnology company in the Houston area. Ms. Park took the company public.

Bronco Technology, Inc. recently contracted with Bayer Services Technology to launch the US Market for Zeptosens’ protein array technology.

Ms. Park was in Diagnostics and Cancer Research at Baylor College of Medicine and UT MD Anderson Cancer Center. One of her greatest accomplishments was the development of the first diagnostic blood test for detection of cancer in the livers of children without having to perform a liver biopsy. She diagnosed and discovered she had a parathyroid tumor using this test.

Ms. Park is past President of the Houston chapter of The National Association of Women Business Owners (NAWBO) and Medical Center Business and Professional Women’s organization. Ms. Park sits on several Boards including Clinical Ligand Assay Society, Women's Chamber of Commerce of Texas, Downs Syndrome Foundation of Houston and others. While president of Houston NAWBO, the organization achieved its first Healthy Chapter award, Bridge Builder award, and various other honors. She raised over $40,000 after beginning the year in the red. Ms. Park is charter member of The Woodlands Delta Zeta Alumni Chapter. She was president of Annie Gibbs Society at Sam Houston State Teachers College the year national sororities came on campus. Ms. Park always jumps in with a “lets go” attitude.

She is a former University and High School Instructor. Ms. Park holds a BS degree in chemistry from Sam Houston State University and a MS degree in biochemistry from Baylor University College of Medicine.

[soupoftheday]

Is this the business we're going into???

Pluristem Life Systems, Inc. is a life sciences driven company that is developing and commercializing stem cell expansion technology products for the treatment of severe blood disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. Its first adult stem cell product is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.

http://www.pluristem.com

PLURISTEM THERAPEUTC(NasdaqCM: PSTI) http://finance.yahoo.com/q?s=PSTI

[soupoftheday]

Helen R. Park was elected as the Company’s Chief Executive Officer and Secretary as of June 16, 2003.

Advanced Bio/Chem, Inc.

http://www.getfilings.com/o0001059677-04-000018.html